Eric Beausoleil

USPTO Granted Patents = 16 (Patent Applications = 3)

CIPO Patents = 1

EPO Patents = 9 (Patent Applications = 8)

Average Co-Inventor Count = 4.4

ph-index = 5

Forward Citations = 53(Granted Patents)

Location History:

San Francisco, CA (US) (2004)
Clamart, FR (2008)
Paris, FR (2006 - 2018)

Company Filing History:

Exonhit Therapeutics, Sa

Novartis Vaccines & Diagnostics, Gmbh

patents

where one patent can have more than one assignee

Years Active: 2004-2018

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9902710 - Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) (2018-02-27),

2. 9670181 - Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) (2017-06-06),

3. 9278943 - Methods of using as analgesics 1-benzyl-1-hydroxy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds (2016-03-08),

4. 9200016 - Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) (2015-12-01),

5. 8927589 - 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-aminopropionic acid amides and related compounds having analgesic and/or immuno stimulant activity (2015-01-06),

6. 8835463 - Compounds having analgesic and/or immunostimulant activity (2014-09-16),

7. 8772316 - Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A) (2014-07-08),

8. 8431599 - 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immuno stimulant activity (2013-04-30),

9. 8288556 - 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immuno stimulant activity (2012-10-16),

10. 8168631 - 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity (2012-05-01),

11. 8153666 - Compounds having analgesic and/or immunostimulant activity (2012-04-10),

12. 8013000 - 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimlant activity (2011-09-06),

13. 7923579 - Tricyclic hydroxamate and benzamide derivatives, compositions and methods (2011-04-12),

14. 7422861 - Oligonucleotide transfection screening method (2008-09-09),

15. 7153682 - Microarrays on mirrored substrates for performing proteomic analyses (2006-12-26),

Title: The Innovative Journey of Eric Beausoleil

Introduction

Eric Beausoleil, based in Paris, France, is a distinguished inventor with an impressive portfolio of 16 patents. His work primarily focuses on pharmaceutical innovations, particularly in the field of central nervous system treatment.

Latest Patents

Among his latest inventions are the "Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)." This remarkable invention relates to specific compounds useful as inhibitors of phosphodiesterase 10, which play a critical role in treating central nervous system diseases, including psychosis. Furthermore, these compounds have potential applications in managing obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain, and ophthalmic diseases. Additionally, he has patented "Substituted 6,7-dialkoxy-3-isoquinolinol derivatives," which shares similar therapeutic benefits, highlighting his significant contribution to medical innovation.

Career Highlights

Eric has had a noteworthy career with major pharmaceutical companies. He has worked with Allergan, Inc. and Exonhit Therapeutics, where his innovative contributions have led to advancements in drug development aimed at improving health outcomes.

Collaborations

Throughout his career, Eric has collaborated with renowned professionals in the industry, including Bertrand Leblond and Thierry Taverne. These collaborations have undoubtedly enriched his research and innovation processes.

Conclusion

Eric Beausoleil’s inventive contributions are paving the way for breakthroughs in medical treatments, particularly for central nervous system disorders. His dedication and expertise continue to inspire advancements in pharmaceutical innovation, making him a key figure in the industry.

This text is generated by artificial intelligence and may not be accurate.